Contemporary clinical guidelines, including the National Comprehensive Cancer Network® (NCCN®) [14] or the European Society for Medical Oncology [15], recommend that gBRCAm is considered alongside HER2 and HR status in treatment decisions for recurrent BC or mBC. Here, ERBB2 is linked to breast cancer.